Intervention not reported
True negativespeople without amikacin resistance · adults with pulmonary tuberculosis with known rifampicin resistance, detected as tuberculosis‐positive by Xpert MTB/XDR Index test: Xpert…
1 finding from 1 review
Intervention not reported
False positivespeople incorrectly classified as having amikacin resistance · adults with pulmonary tuberculosis with known rifampicin resistance, detected as tuberculosis‐positive by Xpert MTB/XDR Index test: Xpert…
1 finding from 1 review
Intervention not reported
Test result · adults with pulmonary tuberculosis irrespective of rifampicin resistance (i.e. whether or not their rifampicin resistance status was…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
True positivespeople with isoniazid resistance · adults with pulmonary tuberculosis irrespective of rifampicin resistance (i.e. whether or not their rifampicin resistance status was…
1 finding from 1 review
Intervention not reported
False negativespeople incorrectly classified as not having isoniazid resistance · adults with pulmonary tuberculosis irrespective of rifampicin resistance (i.e. whether or not their rifampicin resistance status was…
1 finding from 1 review
Intervention not reported
True negativespeople without isoniazid resistance · adults with pulmonary tuberculosis irrespective of rifampicin resistance (i.e. whether or not their rifampicin resistance status was…
1 finding from 1 review
Treatment failure (annual failure rate) · Children with previously unrestored, vital carious lesions in primary teeth (no pulp therapy); aged 1.5-11 years
Conventional GIC had an annual failure rate of 7.6-16.6% (2 RCTs) and failed more than amalgam in one trial; low quality of evidence (ungraded).
1 finding from 1 review
Treatment failure (annual failure rate) by cavity class · Children with carious primary teeth restored in Class-I versus Class-II cavities, no pulp therapy
Class-II restorations failed more than Class-I (annual failure 5-28.9% vs 1.2-14.7% in ART studies); low quality of evidence (ungraded).
1 finding from 1 review
Treatment failure (annual failure rate) · Children (aged 3-8 years) with 2-surface occluso-proximal dentine caries in primary molars, no pulp therapy
Preformed metal (Hall) crowns had a low reported annual failure rate (3.1%) versus compomer (14.7%) in one RCT; low quality of evidence (ungraded).
1 finding from 1 review
Treatment failure (annual failure rate) · Children with previously unrestored, vital carious lesions in primary teeth (no pulp therapy); aged 1.5-11 years
Composite resin (hybrid 0-19.5%; bulk-fill 0-16.9%) performed comparably to or better than most alternatives across 11 RCTs; evidence is of low to unclear quality (ungraded).
1 finding from 1 review
Not applicable (no eligible studies) · Children with carious primary teeth (no pulp therapy)
No eligible RCTs assessed new bio-active restorative materials in carious primary teeth; this is an evidence gap identified by the review.
1 finding from 1 review
Treatment failure (annual failure rate) · Children with previously unrestored, vital carious lesions in primary teeth (no pulp therapy); aged 1.5-11 years
Glass carbomer had very high failure rates (up to 46.2%) in a single RCT, far worse than composite resin or RMGIC; low quality of evidence (ungraded).
1 finding from 1 review
Treatment failure (annual failure rate) · Children with carious primary molars treated by pulpotomy (vital pulp therapy)
Preformed metal crowns had a low annual failure rate (2.4%) in primary molars after pulpotomy, lower than amalgam in the same trial (single high-risk-of-bias RCT; low quality of evidence; not GRADE-rated).
2 findings from 1 review
Mortality Mortality at latest · preventing bronchopulmonary dysplasia in preterm infants
Early systemic postnatal corticosteroids showed no clear difference in mortality at latest reported age compared with placebo or no treatment (high certainty).
1 finding from 1 review
BPD (36 weeks' PMA) · preventing bronchopulmonary dysplasia in preterm infants
Early systemic postnatal corticosteroids probably leads to lower BPD (36 weeks' PMA) compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia at 36 weeks PMA · preventing bronchopulmonary dysplasia in preterm infants
Early systemic postnatal corticosteroids leads to lower mortality or BPD at 36 weeks' PMA compared with placebo or no treatment (high certainty).
1 finding from 1 review
Gastrointestinal perforation during primary hospitalisation · preventing bronchopulmonary dysplasia in preterm infants
Early systemic postnatal corticosteroids leads to higher gastrointestinal perforation during primary hospitalisation compared with placebo or no treatment (high certainty).
1 finding from 1 review
Cerebral palsy · preventing bronchopulmonary dysplasia in preterm infants
Early systemic postnatal corticosteroids leads to higher cerebral palsy at latest reported age compared with placebo or no treatment (high certainty).
1 finding from 1 review
Death or cerebral palsy · preventing bronchopulmonary dysplasia in preterm infants
Early systemic postnatal corticosteroids showed no clear difference in mortality or cerebral palsy at latest reported age compared with placebo or no treatment (high certainty).
1 finding from 1 review
Meters change from baseline in 6MWD · pulmonary arterial hypertension
1 finding from 1 review